LYEL vs. AVBP, AVTE, IGMS, OLMA, GHRS, STOK, CMPS, OCS, PHAT, and CALT
Should you be buying Lyell Immunopharma stock or one of its competitors? The main competitors of Lyell Immunopharma include ArriVent BioPharma (AVBP), Aerovate Therapeutics (AVTE), IGM Biosciences (IGMS), Olema Pharmaceuticals (OLMA), GH Research (GHRS), Stoke Therapeutics (STOK), COMPASS Pathways (CMPS), Oculis (OCS), Phathom Pharmaceuticals (PHAT), and Calliditas Therapeutics AB (publ) (CALT). These companies are all part of the "pharmaceutical preparations" industry.
ArriVent BioPharma (NASDAQ:AVBP) and Lyell Immunopharma (NASDAQ:LYEL) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, institutional ownership, analyst recommendations, risk, valuation, community ranking, media sentiment, dividends and profitability.
Lyell Immunopharma received 6 more outperform votes than ArriVent BioPharma when rated by MarketBeat users. However, 100.00% of users gave ArriVent BioPharma an outperform vote while only 56.52% of users gave Lyell Immunopharma an outperform vote.
ArriVent BioPharma presently has a consensus price target of $29.25, indicating a potential upside of 65.25%. Lyell Immunopharma has a consensus price target of $5.50, indicating a potential upside of 123.58%. Given ArriVent BioPharma's higher probable upside, analysts clearly believe Lyell Immunopharma is more favorable than ArriVent BioPharma.
9.5% of ArriVent BioPharma shares are owned by institutional investors. Comparatively, 66.1% of Lyell Immunopharma shares are owned by institutional investors. 24.0% of Lyell Immunopharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
ArriVent BioPharma has a net margin of 0.00% compared to ArriVent BioPharma's net margin of -335,794.09%. Lyell Immunopharma's return on equity of 0.00% beat ArriVent BioPharma's return on equity.
ArriVent BioPharma has higher earnings, but lower revenue than Lyell Immunopharma.
In the previous week, Lyell Immunopharma had 4 more articles in the media than ArriVent BioPharma. MarketBeat recorded 13 mentions for Lyell Immunopharma and 9 mentions for ArriVent BioPharma. Lyell Immunopharma's average media sentiment score of 1.27 beat ArriVent BioPharma's score of 0.13 indicating that ArriVent BioPharma is being referred to more favorably in the media.
Summary
ArriVent BioPharma beats Lyell Immunopharma on 8 of the 14 factors compared between the two stocks.
Get Lyell Immunopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for LYEL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LYEL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lyell Immunopharma Competitors List
Related Companies and Tools
